Comment on: Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin

Niels Adriaenssens1,2*, Herman Goossens1 and Samuel Coenen1–3 on behalf of the ESAC Project Group

1Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium; 2Centre for General Practice, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium; 3Research Foundation - Flanders, Brussels, Belgium

Keywords: antibiotic use, route of administration, drug consumption, pharmacoepidemiology, ambulatory care

*Corresponding author. E-mail: niels.adriaenssens@ua.ac.be

Sir,

With great interest we have read the review by Dilip Nathwani in the September issue of JAC.1 The author refers to our work2 when stating that outpatient parenteral antibiotic treatment (OPAT) accounts for >1% of total outpatient antibiotic use in only 6 out of 20 European countries. Meanwhile, the work on OPAT by the European Surveillance of Antimicrobial Consumption (ESAC) Project Group has made some progress. We have excluded three countries from the analysis, because these countries could not distinguish between ambulatory care and hospital antibiotic use, and we have included data for three more European countries. To our best and current knowledge, recently published in JAC,3 OPAT represents >1% of total outpatient antibiotic use in only 3 out of 20 European countries, i.e. Russia, Italy and Poland.

Transparency declarations

None to declare.

References